Stock listing

TG1N Stock Price, News, Filings & Events — Armata Pharmaceuticals, Inc.

Selected listing: TG1N · GETTEX · EUR · DE

This page tracks Armata Pharmaceuticals, Inc.'s TG1N:GETTEX listing on GETTEX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following TG1N:GETTEX. TG1N:GETTEX is the stock-level entry point for investors researching Armata Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Armata Pharmaceuticals, Inc. (ticker: ARMP) is a public company based in the United States, focusing on innovative therapies for bacterial infections. With a market capitalization of approximately $165.6 million, Armata is dedicated to advancing its pipeline of treatments aimed at addressing unmet medical needs in infectious diseases. The company is committed to developing solutions that improve patient outcomes and...

TG1N:GETTEXEURDEUpdated September 12, 2026

Ticker: TG1N:GETTEX
Asset type: Stock
Market cap: $200.0M
Sector: Health Technology
Industry: Biotechnology
Exchange: GETTEX
Currency: EUR

Armata Pharmaceuticals, Inc. TG1N:GETTEX stock context

Latest news from Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

August 12, 2026

Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphyloc...

July 13, 2026

Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02

June 23, 2026

Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update

May 13, 2026

Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02

May 7, 2026

All Armata Pharmaceuticals, Inc. news →

Research Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. investor report

Review AI stock analysis and investor report context for TG1N:GETTEX.

Armata Pharmaceuticals, Inc. company profile

View the public company page for Armata Pharmaceuticals, Inc. on 6ix.

Armata Pharmaceuticals, Inc. news

Read company news and market updates connected to Armata Pharmaceuticals, Inc..

Armata Pharmaceuticals, Inc. investor events

Find investor webinars, events, and replay context for Armata Pharmaceuticals, Inc..